Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia

QJM. 2017 Jan;110(1):53-54. doi: 10.1093/qjmed/hcw206. Epub 2016 Dec 22.

Authors

A Fountas¹, S Tigas², A Tsatsoulis²

Affiliations

¹ From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece [email protected].
² From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.

PMID: 28011856
DOI: 10.1093/qjmed/hcw206

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Denosumab
Humans
Hypercalcemia*
Paraneoplastic Syndromes
Parathyroid Hormone
Parathyroid Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
Parathyroid Hormone
Denosumab